Examining Monocyte Profiles in Critically Ill Patients with Pseudomonas Aeruginosa Sepsis
Phenotypical Und Functional Characterization of Macrophages in Critically Ill Patients With Pseudomonas Aeruginosa Induced Sepsis
This study is trying to see if the type of immune cells in the blood of critically ill patients with sepsis from Pseudomonas aeruginosa can tell us more about how sick they are and how they might recover.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University of Ulm Academic / other |
| Locations | 1 site (Ulm) |
| Trial ID | NCT03044223 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the characteristics of blood monocytes in critically ill patients suffering from sepsis caused by Pseudomonas aeruginosa. It aims to determine whether the pro-inflammatory M1 or anti-inflammatory M2 monocyte phenotype predominates in these patients and how this relates to the severity of sepsis and patient outcomes. The study employs flow cytometry to analyze surface marker expression and ELISA to assess cytokine patterns in blood samples. Additionally, an ex-vivo model for Pseudomonas-induced sepsis will be validated to further understand the immune response.
Who should consider this trial
Good fit: Ideal candidates include critically ill adults over 18 years old with microbiologically confirmed Pseudomonas aeruginosa infections.
Not a fit: Patients with a life expectancy of less than 24 hours or those participating in other studies may not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of immune responses in sepsis, potentially guiding more effective treatments for patients.
How similar studies have performed: Previous studies have indicated the importance of monocyte polarization in sepsis, suggesting that this approach may yield valuable insights, although this specific focus on Pseudomonas aeruginosa is less commonly explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \> 18 years * critically ill patients with sepsis * microbiologically proven infection with Pseudomonas aeruginosa Exclusion Criteria: * life expectancy \< 24 hours * participation in other studies
Where this trial is running
Ulm
- Clinic of Anesthesiology — Ulm, Germany (Recruiting)
Study contacts
- Principal investigator: Manfred Weiss, MD, MBA — University Ulm, University Hospital Ulm
- Study coordinator: Manfred Weiss, MD, MBA
- Email: manfred.weiss@uniklinik-ulm.de
- Phone: +49 731 500 60226
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.